

**RECORDATI: THE BOARD OF DIRECTORS APPROVES THE CROSS BORDER MERGER BY ABSORPTION OF THE SUBSIDIARY RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY BY RECORDATI S.p.A.**

Milan, April 5, 2017 – Please be informed that today the Board of Directors of Recordati S.p.A., following the resolution approving the merger project disclosed to the public on March 1, 2017, approved, pursuant to article 2505 paragraph 2 of the Italian Civil Code, as allowed by article 22 of Company's Bylaws, as well as pursuant to the Italian Legislative Decree n.108/2008, the cross border merger by absorption by Recordati S.p.A. of the Luxembourg company Recordati S.A. Chemical and Pharmaceutical Company, entirely held by the former.

As for any other information relating to such transaction, please make reference to the press releases already disclosed, as well as to the Board of Directors management report to the merger and to the Merger Project, which are available to the public at the Company's registered office and published on the Company's website ([www.recordati.it](http://www.recordati.it); Section Corporate Governance, Other Corporate Documents) and on the authorized storage mechanism managed by Computershare S.p.A. ([www.1info.it](http://www.1info.it)).

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa, in the United States of America, in Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2016 was € 1,153.9 million, operating income was € 327.4 million and net income was € 237.4 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

Investor Relations

Marianne Tatschke  
(39)0248787393  
e-mail: [inver@recordati.it](mailto:inver@recordati.it)

Media Relations

Studio Noris Morano  
(39)0276004736, (39)0276004745  
e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.  
REG. IMP. MILANO N. 00748210150  
CODICE FISCALE/P.IVA 007482210150  
R.E.A. MILANO N. 401832